New drug reduced renal damage in septic patients
Drug Discovery World
JANUARY 19, 2023
A pilot Phase IIa clinical trial evaluating Abionyx Pharma’s CER-001 as a treatment for septic patients at high risk of developing acute kidney injury (AKI) has met its primary endpoint. million related deaths globally. “The trial shows promising positive results across a variety of primary and secondary endpoints.
Let's personalize your content